Study of predictive factors of complete response after chemoembolization for unresectable hepatocellular carcinoma in 162 patients.
HCC
TACE
complete response
Journal
Clinical and experimental hepatology
ISSN: 2392-1099
Titre abrégé: Clin Exp Hepatol
Pays: Poland
ID NLM: 101703431
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
23
04
2020
accepted:
28
07
2020
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
30
1
2021
Statut:
ppublish
Résumé
To study clinical, laboratory and imaging features correlated with complete response (CR) to transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC) through 162 patients collected in Hassan II University Hospital of Fez. From January 2015 to December 2019, 162 patients diagnosed with 225 HCC were treated by TACE. Among them, 14 showed CR during the follow-up. Imaging response was evaluated using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). A multivariate analysis was performed including demographic parameters, etiology, α-fetoprotein (AFP) rates, hepatic function scores, imaging and TACE features. In cases with complete response and remission, follow-up duration was considered from the first to the last imaging control showing no viable tumor and eventually nodule retraction. Among the 162 patients with 225 nodules, 14 (9%) of them showed remission and 148 (91%) did not. There was no significant difference between the two groups in age, performance status (PS), AFP, nodularity, size nodule or number of TACE cures. Sex, etiology, Child-Pugh and MELD scores, location, BCLC stage and blush extinction were all found to have a significant impact on therapeutic response. This study demonstrates that CR of HCC treated by TACE is strongly correlated with male sex, etiology (viral hepatitis C), location (segments VI and VII) and complete blush extinction on digital subtraction angiography (DSA). No significant correlation was found, particularly that of tumor size and segment IV (as a pejorative location).
Identifiants
pubmed: 33511278
doi: 10.5114/ceh.2020.102169
pii: 42853
pmc: PMC7816630
doi:
Types de publication
Journal Article
Langues
eng
Pagination
313-320Informations de copyright
Copyright: © 2020 Clinical and Experimental Hepatology.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
HPB (Oxford). 2014 Apr;16(4):327-35
pubmed: 23980917
Tumour Biol. 2012 Feb;33(1):33-40
pubmed: 21931992
Surgery. 1993 Jun;113(6):612-8
pubmed: 8389492
J Clin Oncol. 2009 Dec 1;27(34):5734-42
pubmed: 19805671
J Vasc Interv Radiol. 2013 Apr;24(4):509-17
pubmed: 23428355
Eur Radiol. 2016 Jun;26(6):1640-8
pubmed: 26455721
Radiology. 2013 Feb;266(2):636-48
pubmed: 23143027
Gastroenterol Clin Biol. 2002 Aug-Sep;26(8-9):728-34
pubmed: 12434077
Br J Cancer. 2005 May 23;92(10):1862-8
pubmed: 15870713
J Immunother. 2007 May-Jun;30(4):425-37
pubmed: 17457217
Gastroenterology. 2008 May;134(6):1752-63
pubmed: 18471552
Clin Mol Hepatol. 2016 Mar;22(1):7-17
pubmed: 27044761
Cancer. 2003 Feb 15;97(4):1042-50
pubmed: 12569604
Hepatol Res. 2013 Dec;43(12):1304-12
pubmed: 23442052
Liver Transpl. 2012 Jun;18(6):727-36
pubmed: 22344899
Eur J Radiol. 2012 Mar;81(3):466-71
pubmed: 21376495
Gastroenterology. 2006 Aug;131(2):461-9
pubmed: 16890600
Gut Liver. 2017 May 15;11(3):409-416
pubmed: 28208001
World J Hepatol. 2016 Apr 8;8(10):471-84
pubmed: 27057305